Active, not recruitingNot applicableNCT03936829
Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
Studying Acquired generalized lipodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Fudan University
- Principal Investigator
- Feihong LuoChildren's Hospital of Fudan University
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 10 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2030
Study locations (1)
- Children's Hospital of Fudan University, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03936829 on ClinicalTrials.govOther trials for Acquired generalized lipodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07220785Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyRegeneron Pharmaceuticals
- RECRUITINGPHASE3NCT06502990Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyAmryt Pharma
- ACTIVE NOT RECRUITINGPHASE3NCT06548100A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)Regeneron Pharmaceuticals
- RECRUITINGNCT03553420Registry for Patients With LipodystrophyUniversity of Ulm
- ACTIVE NOT RECRUITINGPHASE3NCT02262832Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)